Peptide-drug Conjugate BL0020 clinical trials
Also written BL0020.
Developed by Shanghai Best-Link Bioscience: 3 company-led studies, furthest phase 2. Its development, company by company →
How each study uses Peptide-drug Conjugate BL0020 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Peptide-drug Conjugate BL0020 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BL0020
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Best-Link Bioscience, LLC (3)
Studies
Open first, then newest update. How each study uses Peptide-drug Conjugate BL0020 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung CancerNot yet recruitingPhase 1Shanghai Best-Link Bioscience, LLCNCT07550842Written as BL0020
- A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI TherapyNot yet recruitingPhase 1/2Shanghai Best-Link Bioscience, LLCNCT07414927Written as BL0020
- Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid TumorsRecruitingPhase 1Shanghai Best-Link Bioscience, LLCNCT05886868Written as BL0020